Updated time: 2021-11-10 19:38:20
33T-1101029
2021-11-10
Know-how
We used flow cytometer to isolate memory B cells from COVID-19 vaccinated people and employed human single B cell RT-PCR technology to generate human monoclonal antibodies (hAbs) against receptor binding domain (RBD) of SARS-CoV-2 spike (Spike) protein. ELISA technology showed that these antibodies have strong binding activity to RBD of wild strains (Wuhan), British strains (Alpha, B.1.1.7), and Indian strains (Delta, B.1.617.2). Among of them, 3 hAbs exhibited high levels of neutralizing performance against SARS-COV-2 spike protein-expressed lentivirus, including Alpha variant (B.1.1.7) and Delta variant (B.1.617.2). Therefore, these data suggest that three human antibodies have a clinical potential for the treatment of COVID-19.
- Human antibodies have high specificity, low immune rejection and few side effects.
- Anti-RBD hAbs have high neutralization activity and can be used to develop therapeutic antibodies.
- High neutralization ability to the dominant strain of SARS-COV-2, Delta variant, that is currently pandemic in the world.
- Development of therapeutic antibody drug for COVID-19.
Han-Chung Wu, Ruei-Min Lu, Pao-Yin Chiang, Hsiao-Ling Chiang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Neutralizing Human Antibodies from Single B cells